341 related articles for article (PubMed ID: 29266879)
1. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
[TBL] [Abstract][Full Text] [Related]
3. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
[TBL] [Abstract][Full Text] [Related]
5. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S; Libby P; Husni E; Wang Q; Wisniewski LM; Davey DA; Wolski KE; Xia F; Bao W; Walker C; Ruschitzka F; Nissen SE; Lüscher TF
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):611-621. PubMed ID: 35234840
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
7. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
[TBL] [Abstract][Full Text] [Related]
8. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
Reed GW; Abdallah MS; Shao M; Wolski K; Wisniewski L; Yeomans N; Lüscher TF; Borer JS; Graham DY; Husni ME; Solomon DH; Libby P; Menon V; Lincoff AM; Nissen SE
J Am Coll Cardiol; 2018 Apr; 71(16):1741-1751. PubMed ID: 29673465
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
10. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
12. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
13. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Solomon DH; Shao M; Wolski K; Nissen S; Husni ME; Paynter N
Arthritis Rheumatol; 2019 Aug; 71(8):1225-1231. PubMed ID: 30801994
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
Moore RA; Derry S; Makinson GT; McQuay HJ
Arthritis Res Ther; 2005; 7(3):R644-65. PubMed ID: 15899051
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
Mallen SR; Essex MN; Zhang R
Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
[TBL] [Abstract][Full Text] [Related]
16. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Eversmeyer W; Poland M; DeLapp RE; Jensen CP
Am J Med; 1993 Aug; 95(2A):10S-18S. PubMed ID: 8356997
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
[TBL] [Abstract][Full Text] [Related]
20. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
van Walsem A; Pandhi S; Nixon RM; Guyot P; Karabis A; Moore RA
Arthritis Res Ther; 2015 Mar; 17(1):66. PubMed ID: 25879879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
